Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Histologically documented large B-cell, CD20-positive non-Hodgkin's lymphoma~* No previous treatment~* Clinical stage II, III, or IV by the Ann Arbor Staging Criteria~* Age \> 70 years~* ECOG performance status 0, 1, or 2~* Adequate bone marrow, liver and kidney function~* Must give written informed consent prior to entering this trial~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* Central nervous system involvement with lymphoma~* Coexistent active malignancies treated within five years~* Active infection precluding the use of combination chemotherapy~* HIV infection~* Pregnant or lactating~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide/Vincristine/Rituximab +/- Mitoxantrone (Type: EXPERIMENTAL): All patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).